- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07578740
The Effects of High-Intensity Interval Training on Gait, Balance, and Cognitive Functions in Individuals With Multiple Sclerosis (HIIT-MS)
May 18, 2026 updated by: Kübra Turan, Hacettepe University
Investigating the Effects of High-Intensity Interval Training on Gait, Balance, and Cognition in Individuals With Multiple Sclerosis
This study aims to comparatively investigate the effects of low-volume High-Intensity Interval Training (HIIT) versus Moderate-Intensity Continuous Training (MICT) on gait, balance, cognitive functions, and neurovascular biomarkers (BDNF, VEGF) in individuals with Multiple Sclerosis (MS).
This randomized controlled trial will be conducted at Hacettepe University, Faculty of Physical Therapy and Rehabilitation.
Study Overview
Status
Not yet recruiting
Detailed Description
Individuals with MS aged 18 and older, with an EDSS score of 0-4, no relapse in the past three months, and medically stable condition will be randomized into two groups using a sealed-envelope method.
Group 1 will receive MICT on a cycle ergometer (twice weekly, 8 weeks); Group 2 will receive low-volume HIIT with the same frequency.
Both groups will receive an individualized physiotherapy program after each aerobic session.
Outcomes include gait (TUG, T25FW, DGI), balance (Mini-BESTest, mCTSIB), cognitive function (BICAMS: SDMT, CVLT-II, BVMT-R), exercise capacity (ISWT), and blood biomarkers (BDNF, VEGF) assessed via ELISA.
Study Type
Interventional
Enrollment (Estimated)
40
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Kübra Turan, Msc, PT
- Phone Number: +90 506 516 41 58
- Email: kubraaturann5@gmail.com
Study Locations
-
-
-
Ankara, Turkey (Türkiye)
- Hacettepe University
-
Contact:
- Kübra Turan
- Phone Number: +90 506 516 41 58
- Email: kubraaturann5@gmail.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Diagnosed with Multiple Sclerosis by a neurologist (Hacettepe University Hospitals, Neurology Outpatient Clinic)
- Age 18 years and older
- EDSS score between 0 and 4
- Score of 24 or above on the Standardized Mini Mental State Examination
- No relapse in the past 3 months
- Medically stable for at least 6 months
Exclusion Criteria:
• Any additional cardiopulmonary, neurological, or systemic disease other than MS
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: MICT Group (Moderate-Intensity Continuous Training)
Cycle ergometer-based MICT, twice weekly for 8 weeks, starting at 60% of peak workload, progressing to 80%.
Sessions include 5-min warm-up, 20-30 min exercise, 5-min cool-down, followed by 30-min individualized physiotherapy.
|
Cycle ergometer-based exercise, twice weekly for 8 weeks.
Starting intensity at 60% of peak workload, progressing to 80%.
Each session includes 5-min warm-up, 20-30 min continuous exercise, and 5-min cool-down, followed by 30-min individualized physiotherapy program.
|
|
Experimental: HIIT Group (High-Intensity Interval Training)
HIIT on cycle ergometer, twice weekly for 8 weeks.
Protocol: 5-min warm-up (40% peak workload), 10 × 1-min intervals at 90% peak workload with 1-min active recovery (60% peak workload) between each, followed by 5-min cool-down.
Total session: ~20 min aerobic + 30-min individualized physiotherapy.
|
Cycle ergometer-based exercise, twice weekly for 8 weeks.
Each session includes 5-min warm-up (40% peak workload), 10 × 1-min intervals at 90% peak workload with 1-min active recovery (60% peak workload) between each interval, and 5-min cool-down.
Total aerobic exercise duration: ~20 min, followed by 30-min individualized physiotherapy program.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Timed Up and Go Test (TUG)
Time Frame: Baseline and 8 weeks
|
Timed Up and Go Test (TUG).
Participants are asked to rise from a standard chair, walk 3 meters, turn around, walk back, and sit down as fast as safely possible.
Measured in seconds.
Lower values indicate better functional mobility and balance.
|
Baseline and 8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Serum BDNF levels (ELISA)
Time Frame: Baseline and 8 weeks
|
Baseline and 8 weeks
|
|
|
Serum VEGF levels (ELISA)
Time Frame: Baseline and 8 weeks
|
Baseline and 8 weeks
|
|
|
Timed 25-Foot Walk Test (T25FW)
Time Frame: Baseline and 8 weeks
|
Timed 25-Foot Walk Test (T25FW).
Participants are instructed to walk 7.62 meters (25 feet) as quickly and safely as possible.
Measured in seconds.
Lower values indicate better walking speed.
|
Baseline and 8 weeks
|
|
Dynamic Gait Index (DGI)
Time Frame: Baseline and 8 weeks
|
Dynamic Gait Index (DGI).
Assesses the ability to maintain balance while walking under varied conditions across 8 tasks.
Minimum score: 0, Maximum score: 24.
Higher scores indicate better dynamic gait balance.
|
Baseline and 8 weeks
|
|
Incremental Shuttle Walk Test (ISWT)
Time Frame: Baseline and 8 weeks
|
Incremental Shuttle Walk Test (ISWT).
Participants walk between two cones placed 9 meters apart at increasing speeds guided by audio signals until they can no longer maintain the required pace.
Measured in meters walked.
Higher values indicate better functional exercise capacity.
|
Baseline and 8 weeks
|
|
Mini Balance Evaluation Systems Test (Mini-BESTest)
Time Frame: Baseline and 8 weeks
|
Mini Balance Evaluation Systems Test (Mini BESTest).
Assesses dynamic balance across 14 items in 4 subsections: anticipatory postural control, reactive postural control, sensory orientation, and dynamic gait.
Minimum score: 0, Maximum score: 28.
Higher scores indicate better balance performance.
|
Baseline and 8 weeks
|
|
Modified CTSIB (mCTSIB) - Static Posturography
Time Frame: Baseline and 8 weeks
|
Modified Clinical Test of Sensory Interaction and Balance (mCTSIB).
Assesses static postural stability under 4 conditions: eyes open/closed on firm and foam surfaces.
Postural sway is measured in degrees per second.
Lower values indicate better static balance.
|
Baseline and 8 weeks
|
|
Symbol Digit Modalities Test (SDMT)
Time Frame: Baseline and 8 weeks
|
Part of the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) battery.
Assesses information processing speed in neurological conditions.
Participants are asked to match symbols with corresponding digits within 90 seconds.
Minimum score: 0, Maximum score: 110.
Higher scores indicate better cognitive processing speed.
|
Baseline and 8 weeks
|
|
California Verbal Learning Test-II (CVLT-II)
Time Frame: Baseline and 8 weeks
|
Part of the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) battery.
Assesses auditory and verbal memory.
A list of 16 words across 4 categories is read aloud and recalled over 5 trials.
Minimum score: 0, Maximum score: 80. Higher scores indicate better verbal learning and memory.
|
Baseline and 8 weeks
|
|
Brief Visuospatial Memory Test-Revised (BVMT-R)
Time Frame: Baseline and 8 weeks
|
Part of the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) battery.
Assesses visuospatial memory.
Six geometric figures are presented and participants are asked to reproduce them from memory.
Minimum score: 0, Maximum score: 36.
Higher scores indicate better visuospatial memory.
|
Baseline and 8 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Yeliz SALCI, Hacettepe University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
July 1, 2026
Primary Completion (Estimated)
June 1, 2028
Study Completion (Estimated)
June 1, 2028
Study Registration Dates
First Submitted
May 5, 2026
First Submitted That Met QC Criteria
May 5, 2026
First Posted (Actual)
May 11, 2026
Study Record Updates
Last Update Posted (Actual)
May 20, 2026
Last Update Submitted That Met QC Criteria
May 18, 2026
Last Verified
May 1, 2026
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Nervous System Diseases
- Autoimmune Diseases
- Immune System Diseases
- Demyelinating Autoimmune Diseases, CNS
- Autoimmune Diseases of the Nervous System
- Demyelinating Diseases
- Multiple Sclerosis
- Motor Activity
- Movement
- Musculoskeletal Physiological Phenomena
- Musculoskeletal and Neural Physiological Phenomena
- Physical Conditioning, Human
- Exercise
- High-Intensity Interval Training
Other Study ID Numbers
- FTREK26/19
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Sclerosis
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationRecruitingMultiple Sclerosis (MS) | Relapsing-remitting Multiple Sclerosis (RRMS) | Secondary-progressive Multiple Sclerosis (SPMS) | Primary Progressive Multiple Sclerosis (PPMS)Switzerland
-
University of California, Los AngelesUnknownRelapsing-remitting Multiple Sclerosis | Secondary-progressive Multiple Sclerosis | Primary-progressive Multiple SclerosisUnited States
-
BiogenCompletedMultiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Remittent ProgressiveJapan
-
Cabaletta BioNot yet recruitingProgressive Multiple Sclerosis | Multiple Sclerosis | Multiple Sclerosis (Relapsing Remitting) | Relapsing Multiple Sclerosis (RMS) | Progressive Multiple Sclerosis (PMS) | Multiple Sclerosis (MS) - Relapsing-remitting | Multiple Sclerosis - Relapsing Remitting
-
The Cleveland ClinicUniversity Hospitals Cleveland Medical CenterCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
Rigshospitalet, DenmarkOdense University Hospital; Aarhus University Hospital; Hvidovre University Hospital and other collaboratorsActive, not recruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisDenmark
-
Icahn School of Medicine at Mount SinaiColumbia University; New York Stem Cell Foundation Research InstituteCompletedClinically Isolated Syndrome | Relapsing-Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Novartis PharmaceuticalsCompletedRelapsing-remitting Multiple Sclerosis | Active Secondary Progressive Multiple SclerosisJapan
-
Banc de Sang i TeixitsVall d'Hebron Research Institute (VHIR)CompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisSpain
-
BiogenElan PharmaceuticalsCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
Clinical Trials on Moderate-Intensity Continuous Training (MICT)
-
Riphah International UniversityCompleted
-
Guangdong Provincial People's HospitalRecruiting
-
Guangdong Provincial People's HospitalZhongshan Hospital Of Traditional Chinese MedicineCompletedMyocardial Infarction | Cardiopulmonary Disease | Training Group, SensitivityChina
-
University of Colorado, BoulderCompleted
-
Chang Gung Memorial HospitalNational Science Council, Taiwan; Chang Gung UniversityCompletedHigh Intensity Interval Training | Healthy | Exercise TrainingTaiwan
-
Norwegian University of Science and TechnologyThe University of QueenslandCompleted
-
University of ÉvoraCompletedPatients With Coronary Artery DiseasePortugal
-
Cerini TamaraSchulthess KlinikCompleted
-
Bitlis Eren UniversityCompletedExercise Physiology | Exercise ImmunologyTurkey (Türkiye)
-
Eastern Mediterranean UniversityRecruiting